Shield Therapeutics OTC Stock Forecast - Naive Prediction
| SHIEF Stock | USD 0.15 0.00 0.00% |
The Naive Prediction forecasted value of Shield Therapeutics plc on the next trading day is expected to be 0.14 with a mean absolute deviation of 0.01 and the sum of the absolute errors of 0.38. Shield OTC Stock Forecast is based on your current time horizon. We recommend always using this module together with an analysis of Shield Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 24th of January 2026 the value of rsi of Shield Therapeutics' share price is below 20 . This usually implies that the otc stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
It is a matter of debate whether otc price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Shield Therapeutics based on different types of headlines from major news networks to social media. Using Shield Therapeutics hype-based prediction, you can estimate the value of Shield Therapeutics plc from the perspective of Shield Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Shield Therapeutics plc on the next trading day is expected to be 0.14 with a mean absolute deviation of 0.01 and the sum of the absolute errors of 0.38. Shield Therapeutics after-hype prediction price | USD 0.18 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as otc price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Shield |
Shield Therapeutics Additional Predictive Modules
Most predictive techniques to examine Shield price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Shield using various technical indicators. When you analyze Shield charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Shield Therapeutics Naive Prediction Price Forecast For the 25th of January
Given 90 days horizon, the Naive Prediction forecasted value of Shield Therapeutics plc on the next trading day is expected to be 0.14 with a mean absolute deviation of 0.01, mean absolute percentage error of 0.000069, and the sum of the absolute errors of 0.38.Please note that although there have been many attempts to predict Shield OTC Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Shield Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Shield Therapeutics OTC Stock Forecast Pattern
| Backtest Shield Therapeutics | Shield Therapeutics Price Prediction | Buy or Sell Advice |
Shield Therapeutics Forecasted Value
In the context of forecasting Shield Therapeutics' OTC Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Shield Therapeutics' downside and upside margins for the forecasting period are 0 and 8.29, respectively. We have considered Shield Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Shield Therapeutics otc stock data series using in forecasting. Note that when a statistical model is used to represent Shield Therapeutics otc stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 110.3677 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0061 |
| MAPE | Mean absolute percentage error | 0.056 |
| SAE | Sum of the absolute errors | 0.38 |
Predictive Modules for Shield Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Shield Therapeutics plc. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Shield Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Shield Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Shield Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Shield Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of OTC Stock prices, such as prices of Shield Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Shield Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Shield Therapeutics' otc stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Shield Therapeutics' historical news coverage. Shield Therapeutics' after-hype downside and upside margins for the prediction period are 0.01 and 8.33, respectively. We have considered Shield Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Shield Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Shield Therapeutics plc is based on 3 months time horizon.
Shield Therapeutics OTC Stock Price Prediction Analysis
Have you ever been surprised when a price of a OTC Stock such as Shield Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Shield Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the OTC price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Shield Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.99 | 8.15 | 0.03 | 0.07 | 2 Events / Month | 3 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.15 | 0.18 | 20.00 |
|
Shield Therapeutics Hype Timeline
Shield Therapeutics plc is at this time traded for 0.15. The entity has historical hype elasticity of 0.03, and average elasticity to hype of competition of 0.07. Shield is forecasted to increase in value after the next headline, with the price projected to jump to 0.18 or above. The average volatility of media hype impact on the company the price is over 100%. The price rise on the next news is projected to be 20.0%, whereas the daily expected return is at this time at 0.99%. The volatility of related hype on Shield Therapeutics is about 12164.18%, with the expected price after the next announcement by competition of 0.22. Shield Therapeutics plc has accumulated 156 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Shield Therapeutics plc has a current ratio of 2.55, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Shield Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Shield Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Shield Therapeutics plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Shield to invest in growth at high rates of return. When we think about Shield Therapeutics' use of debt, we should always consider it together with cash and equity.Assuming the 90 days horizon the next forecasted press release will be in a few days. Check out Historical Fundamental Analysis of Shield Therapeutics to cross-verify your projections.Shield Therapeutics Related Hype Analysis
Having access to credible news sources related to Shield Therapeutics' direct competition is more important than ever and may enhance your ability to predict Shield Therapeutics' future price movements. Getting to know how Shield Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Shield Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ORXOF | Orexo AB | 0.08 | 9 per month | 0.00 | 0.09 | 0.00 | 0.00 | 5.90 | |
| GGBXF | Green Growth Brands | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PFGTF | Pacific Edge Limited | 0.00 | 0 per month | 0.00 | (0.03) | 0.00 | 0.00 | 60.82 | |
| LOVFF | Cannara Biotech | 0.38 | 7 per month | 1.74 | 0.08 | 6.56 | (3.45) | 15.50 | |
| JUSHF | Jushi Holdings | 0.09 | 4 per month | 9.48 | 0.02 | 18.33 | (9.84) | 104.05 | |
| POLBF | Poolbeg Pharma PLC | 0.09 | 8 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BIOYF | Biosyent | 0.00 | 0 per month | 1.06 | 0.16 | 3.14 | (1.89) | 9.22 | |
| HLTRF | HLS Therapeutics | 0.08 | 13 per month | 0.00 | (0.29) | 0.00 | (1.98) | 7.96 | |
| GRUSF | Grown Rogue International | 0.00 | 0 per month | 4.57 | 0.02 | 8.70 | (6.98) | 48.44 | |
| KNTPF | Kintor Pharmaceutical Limited | (0.05) | 26 per month | 0.00 | 0.09 | 0.00 | 0.00 | 27.27 |
Other Forecasting Options for Shield Therapeutics
For every potential investor in Shield, whether a beginner or expert, Shield Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Shield OTC Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Shield. Basic forecasting techniques help filter out the noise by identifying Shield Therapeutics' price trends.Shield Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Shield Therapeutics otc stock to make a market-neutral strategy. Peer analysis of Shield Therapeutics could also be used in its relative valuation, which is a method of valuing Shield Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Shield Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Shield Therapeutics otc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Shield Therapeutics shares will generate the highest return on investment. By undertsting and applying Shield Therapeutics otc stock market strength indicators, traders can identify Shield Therapeutics plc entry and exit signals to maximize returns.
Shield Therapeutics Risk Indicators
The analysis of Shield Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Shield Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting shield otc stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.7 | |||
| Standard Deviation | 7.9 | |||
| Variance | 62.4 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Shield Therapeutics
The number of cover stories for Shield Therapeutics depends on current market conditions and Shield Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Shield Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Shield Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Shield Therapeutics Short Properties
Shield Therapeutics' future price predictability will typically decrease when Shield Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Shield Therapeutics plc often depends not only on the future outlook of the potential Shield Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Shield Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 215.9 M | |
| Shares Float | 125.1 M |
Other Information on Investing in Shield OTC Stock
Shield Therapeutics financial ratios help investors to determine whether Shield OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shield with respect to the benefits of owning Shield Therapeutics security.